Methylenetetrahydrofolate reductase (Mthfr C677t) gene polymorphism effect on development of diabetic nephropathy in Egyptien patients with type 2 diabetes mellitus

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 874-880

  Sharaf, Samar M ^a   Gawish, Heba H ^a   Elsherbiny, Enas M ^b  

^a Zagazig University   (Egypt)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

C677T Polymorphism; Diabetic nephropathy; Homocysteine; MTHFR; Type 2 diabetes mellitus

Indexed keywords

EID: 84874850467     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gall M. A., Hougaard P., Borch-Johnsen K., Parving H. H., Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study, BMJ, 1997; 314: 783-788.
2. Gross J. L., de Azevedo M. J., Silveiro S. P., Canani L. H., Caramori M. L., Zelmanovitz T., Diabetic nephropathy: diagnosis, prevention, and treatment, Diabetes Care 2005; 28: 164-176.
3. Shpichinetsky V., Raz I., Friedlander Y., Goldschmidt N., Wexler I. D., Ben-Yehuda A., Friedman G. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr. 2000; 130: 2493-2497.
4. Zintzaras E., Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a metaanalysis. J Hum Genet. 2005; 50: 84-91.
5. Pettitt D. J., Saad M. F., Bennett P. H., Nelson R. G., Knowler, W. C. Familial predisposition to renal disease in 2 generations of Pima-Indians with type-2 (non insulin dependent) diabetes mellitus. Diabetologia 1990; 33: 438.
6. Mudd S. H., Levy H. L., Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill, 1995: 1279-1326.
7. Goyette P., Sumner J. S., Milos R., Duncan A. M. V., Rosenblatt D. S., Matthews R. G., Rozen R. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nature Genet 1994; 7: 195-200.
8. Neugebauer S., Baba T., Watanabe T. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998; 352: 454.
9. Noiri E., Taguchi J. I., Nakao A., Fujita T. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care 2000; 23: 260.
10. Isotalo P. A., Donnelly J. G. Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis. Mol Diagn 2000; 5: 59-66.
11. Okada E., Oida K., Tada H., Asazuma K., Eguchi K., Tohda G., Kosaka S., Takahashi S, Miyamori I. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 1999 Mar; 22 (3): 484-490.
12. Arruda V. R., von Zuben P. M., Chiaparini L. C., Annichino-Bizzacchi J., Costa F. F. The mutation C677T in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-821.
13. Perry I. J., Refsum H., Morris R. W., Ebrahim S. B., Ueland P. M., Shaper A. G. Prospective study of total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
14. Ralph C., Jacobsen D. W. Homocysteine in Health and Disease. Cambridge University Press, Cambridge, UK, 2001; 92-112.
15. Friedman G., Goldschmidt N., Friedlander Y., Ben-Yehuda A., Selhub J., Babaey S., Mendel M., Kidron M., Bar-On H. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentration. J. Nutr. 1999; 129: 1656-1661.
16. W. Y. Almawi, G. Ameen, H. Tamim, R. R. Finan, N. Irani-Hakime. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease, J. Thromb. Thrombol. 2004; 17: 199-205.
17. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
18. Kang S. S., Wong P. W., Bock H. G., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991; 48: 546-551.
19. Parvanova A, Iliev I, Dimitrov BD, Arnoldi F, Zaletel J, Remuzzi G, Ruggenenti P: Hyperhomocyteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes (Letter). Diabetes Care 25: 2361, 2002.
20. Neugebauer S. B., Baba T., Kurokawa K., Watanabe T., Defective homocysteine metabolism as a risk factor for diabetic retinopathy (Letter), Lancet 1997; 349: 473-474.
21. Hultberg B, Agardh E, Andersson A, Brattström L, Isaksson A, Israelsson B, Agardh CD. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus, Scand J Clin Lab Invest. 1991; 51 (3): 277-282.
22. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1201.
23. American Diabetes Association: Nephropathy in diabetes (Position Statement). Diabetes Care 2004; 27 (Suppl. 1): S79-S83.
24. Kang S. S., Wong P. W., Malinow M. R. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann. Rev. Nutr. 1992; 12: 279-298.
25. US Renal Data System: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
26. Valmadrid C. T., Klein R., Moss S. E., Klein B. E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
27. Weisberg, I., Tran, P., Christensen, B., Sibani, S., and Rozen, R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 1998; 64: 169-172.
28. Bagley, P. J., and Selhub, J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. 1998; 95: 13217-13220.
29. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inher Metab Dis 1996; 19: 589-594.
30. Sun, J; Xu, Y; Xue, J; Zhu, Y; Lu, H. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol. 2005; 229: 95-101.
31. Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mahjoub T, Vaxillaire M, Almawi WY. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007; 75: 99-106.
32. Cui WP, Du B, Jia Y, Zhou WH, Liu SM, Cui YC, Ma FZ, Luo P, Miao LN. Is C677T Polymorphism in Methylenetetrahydrofolate Reductase Gene a Risk Factor for Diabetic Nephropathy or Diabetes Mellitus in a Chinese Population?. ARCH MED RES. 2012; 43 (1): 42-50.
33. Maeda M., Yamamoto I., Fukuda M., Motomura T., Nishida M., Nonen S., Fujio Y., Kasayama S., Azuma J. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications. 2008; 22 (2): 119-125.
34. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998; 98 (18): 1848-1852.
35. Stuhlinger, M. C., Tsao, P. S., Her, J. H., Kimoto, M., Balint, R. F., Cooke, J. P. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation, 2001; 104: 2569-2575.
36. Woo K. S., Chook P., Lolin Y. I., Cheung A. S., Chan L. T., Sun Y. Y., Sanderson J. E., Metreweli C., Celermajer D. S. Hyperhomocyst (e) inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997; 96 (8): 2542-2544.
37. Chao C. L., Tsai H. H., Lee C. M., Hsu S. M., Kao J. T., Chien K. L., Sung F. C., Lee Y. T. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999; 147 (2): 379-386.
38. Fryer R. H., Wilson B. D., Gubler D. B., Fitzgerald L. A., Rodgers G. M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells, Arterioscler Thromb. 1993; 13 (9): 1327-1333.
39. Khajuria A., Houston D. S. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis, Blood. 2000; 96 (3): 966-972.
40. Poddar R., Sivasubramanian N., DiBello P. M., Robinson K., Jacobsen D. W. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation. 2001 5; 103 (22): 2717-2723.
41. Passaro A., Calzoni F., Volpato S., Nora E. D., Pareschi P. L., Zamboni P. F., Fellin R., Solini A. Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year followup. J Intern Med. 2003; 254 (3): 264-271.
42. Ralph C, Jacobsen DW. Homocysteine in Health and Disease. Cambridge University Press, Cambridge, UK, 2001; 321-330.